Get the Stockscreener App
9.145
9.62%
-0.985
Gh Research Plc stock is traded at $9.145, with a volume of 279.50K.
It is down -9.62% in the last 24 hours and down -49.11% over the past month.
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.
See More
Previous Close:
$10.13
Open:
$10.28
24h Volume:
279.50K
Relative Volume:
0.69
Market Cap:
$612.38M
Revenue:
-
Net Income/Loss:
$-41.43M
P/E Ratio:
-11.58
EPS:
-0.79
Net Cash Flow:
$-39.97M
1W Performance:
-25.02%
1M Performance:
-49.11%
6M Performance:
-6.68%
1Y Performance:
+7.71%
1-Day Range:
$9.07
$10.36
1-Week Range:
$9.07
$12.33
52-Week Range:
$6.00
$20.50
Gh Research Plc Stock (GHRS) Company Profile
Compare GHRS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GHRS
Gh Research Plc
|
9.17 | 612.38M | 0 | -41.43M | -39.97M | -0.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
488.58 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
688.28 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
634.75 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.40 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
112.82 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Gh Research Plc Stock (GHRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-13-25 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-16-22 | Initiated | H.C. Wainwright | Buy |
| Jun-16-22 | Initiated | ROTH Capital | Buy |
Gh Research Plc Stock (GHRS) Latest News
Why GH Research PLC (GHRS) is Skyrocketing So Far in 2025 - Insider Monkey
Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025 - Insider Monkey
GH Research PLC (GHRS): Among the Best Psychedelic Stocks to Buy in 2025 - Insider Monkey
GH Research (GHRS) to Release Quarterly Earnings on Thursday - MarketBeat
GH Research (NASDAQ:GHRS) Announces Quarterly Earnings Results - MarketBeat
H.C. Wainwright maintains buy on GH Research stock, $40 target - MSN
12 Best Psychedelic Stocks to Buy in 2025 - Insider Monkey
Psychedelic: GH Research, Compass Pathways report earnings results - Yahoo Finance
GH Research (NASDAQ:GHRS) Given New $32.00 Price Target at Stifel Nicolaus - MarketBeat
GH Research Reports Full Year 2024 Financial Results and Provides Business Updates - GlobeNewswire
Form F-3 GH Research PLC - StreetInsider.com
GH Research Reports 2024 Financial Results and Clinical Progress - TipRanks
Can GH Research's Depression Drug Change Treatment Paradigms? Phase 2b Shows Striking 57.5% Remission Rate - StockTitan
Stifel raises GH Research stock target to $32 on strong trial data - Investing.com
Comprehensive Market Analysis of Latest Published Different Types of Depression Reports | DelveInsight - GlobeNewswire Inc.
GH Research PLC (GHRS): Among the Best Performing Small Cap Stocks So Far In 2025 - Insider Monkey
Small-Cap Stocks Surge: GH Research, Society Pass and Reborn Coffee Lead Monday Gainers - HPBL
GHRS Stock Rallies 55% in a Week: Here's What You Should Know - MSN
Cantor Fitzgerald Forecasts GH Research FY2024 Earnings - Defense World
GH Research (NASDAQ:GHRS) Earns Overweight Rating from Analysts at Cantor Fitzgerald - MarketBeat
Cantor Fitzgerald Initiates Coverage of GH Research (GHRS) with Overweight Recommendation - MSN
Cantor Fitzgerald sets GH Research stock Overweight, $14 target By Investing.com - Investing.com Australia
Cantor Fitzgerald sets GH Research stock Overweight, $14 target - MSN
GH Research initiated with an Overweight at Cantor Fitzgerald - TipRanks
Cantor Fitzgerald Initiates GH Research at Overweight -February 13, 2025 at 07:35 am EST - Marketscreener.com
GH Research - The Pharma Letter
These 5 Health Care Stocks Saw The Sharpest Retail Interest Jump Last Week - NewsBreak
GH Research (NASDAQ:GHRS) Shares Gap UpStill a Buy? - MarketBeat
GH Research PLC's (NASDAQ:GHRS) Top Key Executive Florian Schonharting is the most upbeat insider, and their holdings increased by 31% last week - Yahoo Finance
GH Research (NASDAQ:GHRS) Reaches New 12-Month HighWhat's Next? - MarketBeat
GH Research (NASDAQ:GHRS) Stock Price Down 7.6%Here's What Happened - MarketBeat
GH Research PLC (NASDAQ: GHRS) Up 56.77% From 52-Week Low; YTD Jumps 98.21% – Here’s What To Do Now - Marketing Sentinel
GH Research (NASDAQ:GHRS) Shares Gap DownHere's What Happened - MarketBeat
GH Research (NASDAQ:GHRS) Hits New 1-Year HighShould You Buy? - MarketBeat
GH Research PLC Raises $139.8 Million Through Share Offering - TipRanks
Taking on analysts’ expectations and winning: GH Research PLC (GHRS) - SETE News
Financial Metrics Unveiled: GH Research PLC (GHRS)’s Key Ratios in the Spotlight - The Dwinnex
Where are the Opportunities in (GHRS) - Stock Traders Daily
GH Research PLC (GHRS) stock: A year of ups and downs - US Post News
GH Research Secures $150 Million in Public Offering - TipRanks
Gh Research Plc Stock (GHRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.23%
1.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):